Building Markets Based on Molecular Medicine
Genomic Healthcare Strategies helps companies pursue opportunities related to molecular medicine. Our sole focus is on molecular medicine and its commercial implications for healthcare and wellness, broadly defined.
We believe that the new science and the new insights of molecular medicine (e.g., genomics, proteomics, metabolomics) are fundamentally changing healthcare in the US and around the world.
To quote former FDA commissioner Andrew von Eschenbach: “…that transformation [to molecular medicine] …is so profound and so radical that I call it a metamorphosis: a molecular metamorphosis in which the future of health and healthcare will be no more like the past than a butterfly is like a caterpillar. It is that radical. It is that profound. And it will alter and change not just one thing; it will change everything.”
GHS consults with a range of companies, from Fortune 50 firms to venture-funded start-ups. We help organizations form strategies and deploy their resources in order to take advantage of opportunities and avoid vulnerabilities in rapidly changing healthcare markets.